Статті в журналах з теми "BRAF35"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "BRAF35".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Rugerio-Martínez, Claudia Ivette, Daniel Ramos, Abel Segura-Olvera, Nadia Mireya Murillo-Melo, Yessica Sarai Tapia-Guerrero, Raúl Argüello-García, Norberto Leyva-García, Oscar Hernández-Hernández, Bulmaro Cisneros, and Rocío Suárez-Sánchez. "Dp71 Point Mutations Induce Protein Aggregation, Loss of Nuclear Lamina Integrity and Impaired Braf35 and Ibraf Function in Neuronal Cells." International Journal of Molecular Sciences 23, no. 19 (October 6, 2022): 11876. http://dx.doi.org/10.3390/ijms231911876.
Повний текст джерелаMi LEE, Young, and Wankee KIM. "Association of human kinesin superfamily protein member 4 with BRCA2-associated factor 35." Biochemical Journal 374, no. 2 (September 1, 2003): 497–503. http://dx.doi.org/10.1042/bj20030452.
Повний текст джерелаHakimi, M. A., D. A. Bochar, J. Chenoweth, W. S. Lane, G. Mandel, and R. Shiekhattar. "A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes." Proceedings of the National Academy of Sciences 99, no. 11 (May 28, 2002): 7420–25. http://dx.doi.org/10.1073/pnas.112008599.
Повний текст джерелаZanchetta, Melania E., Luisa M. R. Napolitano, Danilo Maddalo, and Germana Meroni. "The E3 ubiquitin ligase MID1/TRIM18 promotes atypical ubiquitination of the BRCA2-associated factor 35, BRAF35." Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1864, no. 10 (October 2017): 1844–54. http://dx.doi.org/10.1016/j.bbamcr.2017.07.014.
Повний текст джерелаCeballos-Chavez, M., S. Rivero, P. Garcia-Gutierrez, M. Rodriguez-Paredes, M. Garcia-Dominguez, S. Bhattacharya, and J. C. Reyes. "Control of neuronal differentiation by sumoylation of BRAF35, a subunit of the LSD1-CoREST histone demethylase complex." Proceedings of the National Academy of Sciences 109, no. 21 (May 8, 2012): 8085–90. http://dx.doi.org/10.1073/pnas.1121522109.
Повний текст джерелаLee, Belinda, Angelyn Anton, Margaret Lee, Rachel Wong, Phillip Parente, Jeremy David Shapiro, Desmond Yip, et al. "Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC)." Journal of Clinical Oncology 35, no. 4_suppl (February 1, 2017): 728. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.728.
Повний текст джерелаOsterlund, Pia J., Emerik Osterlund, Aki Uutela, Päivi Halonen, Raija S. Kallio, Annika Ålgars, Tapio Salminen, et al. "Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 3532. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3532.
Повний текст джерелаBraithwaite, Matthew, Christopher Duane Nevala-Plagemann, Kelsey Baron, Benjamin Haaland, Lisa M. Pappas, and Ignacio Garrido-Laguna. "Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 4030. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4030.
Повний текст джерелаHernandez-Aya, Leonel Fernando, Matthew Burke, Jenna M. Collins, Dennis Earle, Melissa Hamilton, Beth L. Nordstrom, Ying Zhang, and Shivani Srivastava. "Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e22036-e22036. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22036.
Повний текст джерелаTrunk, Andrew, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna. "Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States." Journal of the National Comprehensive Cancer Network 20, no. 2 (February 2022): 144–50. http://dx.doi.org/10.6004/jnccn.2021.7059.
Повний текст джерелаNordstrom, Beth L., Melissa Hamilton, Jenna M. Collins, Dennis Earle, Ying Zhang, Shivani Srivastava, and Leonel Hernandez-Aya. "Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma." Future Oncology 18, no. 11 (April 2022): 1343–55. http://dx.doi.org/10.2217/fon-2021-0340.
Повний текст джерелаVergidis, Joanna, Richard John Klasa, Youwen Zhou, Elena Moon, Debbie Jepson, and Kerry J. Savage. "Outcome and prognostic factors in BRAF mutation positive metastatic melanoma treated with a BRAF inhibitor: A population-based study in British Columbia." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e20045-e20045. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20045.
Повний текст джерелаMa, Michelle W., Joshua Andrew Farhadian, Erica Brooke Friedman, Eleazar Vega-Saenz de Miera, Douglas Hanniford, Miguel F. Segura, Russell S. Berman, et al. "MicroRNA alterations associated with BRAF status in melanoma." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 8565. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8565.
Повний текст джерелаKarreth, Florian, Markus Reschke, Bjoern Chapuy, Margaret A. Shipp, Roberto Chiarle, and Pier Paolo Pandolfi. "The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA." Blood 124, no. 21 (December 6, 2014): 263. http://dx.doi.org/10.1182/blood.v124.21.263.263.
Повний текст джерелаQiang, Ya-Wei, Shiqiao Ye, Yu Chen, Joshua Epstein, Brian A. Walker, Frits van Rhee, Gareth Morgan, and Faith E. Davies. "Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma." Blood 132, Supplement 1 (November 29, 2018): 3166. http://dx.doi.org/10.1182/blood-2018-99-117459.
Повний текст джерелаDuggan, Megan C., Andrew R. Stiff, Maryam Bainazar, Kelly Regan, Gonzalo N. Olaverria Salavaggione, Sophia Maharry, James S. Blachly, et al. "Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma." Proceedings of the National Academy of Sciences 114, no. 36 (August 21, 2017): 9629–34. http://dx.doi.org/10.1073/pnas.1704371114.
Повний текст джерелаXu, Zhiyuan, Cheng-Chia Lee, Arjun Ramesh, Adam C. Mueller, David Schlesinger, Or Cohen-Inbar, Han-Hsun Shih, and Jason P. Sheehan. "BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases." Journal of Neurosurgery 126, no. 3 (March 2017): 726–34. http://dx.doi.org/10.3171/2016.2.jns1633.
Повний текст джерелаCybulska-Stopa, Bozena, Anna Malgorzata Czarnecka, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska, et al. "Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?" Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e21544-e21544. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21544.
Повний текст джерелаCybulska-Stopa, Bozena, Anna Malgorzata Czarnecka, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska, et al. "Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?" Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e21544-e21544. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21544.
Повний текст джерелаPark, Jongwhi, Hope Lancero, Emon Nasajpour, Cesar Garcia, Laura Prolo, Gerald Grant, and Claudia Petritsch. "STEM-15. THERAPY-INDUCED CHANGES BY BRAF AND MEK INHIBITORS IN BRAF V600E-MUTATED GLIOMA MODELS PROVIDE POTENTIAL NOVEL THERAPEUTIC OPPORTUNITIES." Neuro-Oncology 24, Supplement_7 (November 1, 2022): vii34. http://dx.doi.org/10.1093/neuonc/noac209.132.
Повний текст джерелаWichmann, Jürgen, Caroline Rynn, Thomas Friess, Jeannine Petrig-Schaffland, Martin Kornacker, Cornelia Handl, Jasmin Emmenegger, et al. "Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor." Clinical Cancer Research 28, no. 4 (November 15, 2021): 770–80. http://dx.doi.org/10.1158/1078-0432.ccr-21-2761.
Повний текст джерелаGebhardt, Kathleen, Bayram Edemir, Elisabeth Groß, Linda Nemetschke, Stefanie Kewitz-Hempel, Rose K. C. Moritz, Cord Sunderkötter, and Dennis Gerloff. "BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma." Cancers 13, no. 10 (May 15, 2021): 2393. http://dx.doi.org/10.3390/cancers13102393.
Повний текст джерелаTanaka, Yuka, Maho Murata, Che-Hung Shen, Masutaka Furue, and Takamichi Ito. "NECTIN4: A Novel Therapeutic Target for Melanoma." International Journal of Molecular Sciences 22, no. 2 (January 19, 2021): 976. http://dx.doi.org/10.3390/ijms22020976.
Повний текст джерелаMenzer, Christian, Alexander M. Menzies, Matteo S. Carlino, Irene Reijers, Emma J. Groen, Thomas Eigentler, Jan Willem B. de Groot, et al. "Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations." Journal of Clinical Oncology 37, no. 33 (November 20, 2019): 3142–51. http://dx.doi.org/10.1200/jco.19.00489.
Повний текст джерелаGoldinger, Simone M., Carla Murer, Pascale Stieger, and Reinhard Dummer. "Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 9071. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9071.
Повний текст джерелаPelster, Meredith S., and Rodabe N. Amaria. "Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials." Therapeutic Advances in Medical Oncology 11 (January 2019): 175883591983082. http://dx.doi.org/10.1177/1758835919830826.
Повний текст джерелаNobre, Liana, Michal Zapotocky, Vijay Ramaswamy, Scott Ryall, Julie Bennett, Julia Balaguer Guill, Lorena Baroni, et al. "PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION." Neuro-Oncology 21, Supplement_6 (November 2019): vi184—vi185. http://dx.doi.org/10.1093/neuonc/noz175.771.
Повний текст джерелаHicks, Hannah M., Veronica L. Espinoza, Sharon B. Sams, Nikita Pozdeyev, and Rebecca E. Schweppe. "Abstract 2434: The role of a more invasive phenotype in response to MAPK-directed therapies in thyroid cancer." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2434. http://dx.doi.org/10.1158/1538-7445.am2022-2434.
Повний текст джерелаKefford, Richard, Wilson H. Miller, Daniel Shao-Weng Tan, Ryan J. Sullivan, Georgina Long, Rodrigo Dienstmann, Wai Meng David Tai, et al. "Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 9029. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9029.
Повний текст джерелаRossi, Ernesto, Giovanni Schinzari, Francesco Cellini, Mario Balducci, Mariangela Pasqualoni, Brigida Anna Maiorano, Bruno Fionda, et al. "Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma." Biomedicines 11, no. 2 (January 29, 2023): 394. http://dx.doi.org/10.3390/biomedicines11020394.
Повний текст джерелаNobre, Liana, Michal Zapotocky, Vijay Ramaswamy, Scott Ryall, Julie Bennet, Daniel Alderete, Julia Balaguer Guill, et al. "LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii377. http://dx.doi.org/10.1093/neuonc/noaa222.433.
Повний текст джерелаMuldoon, Daniel, Guisheng Zhao, Carly Batt, Mallika Singh, and Theodore Nicolaides. "MODL-17. SHP2 INHIBITORS SHOW ACTIVITY AGAINST NF1-DEFICIENT GLIOMAS AND ENHANCE MAPK PATHWAY INHIBITION IN BRAF-V600E MUTANT GLIOMAS." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii414. http://dx.doi.org/10.1093/neuonc/noaa222.591.
Повний текст джерелаMadej, Ewelina, Anna A. Brożyna, Agnieszka Adamczyk, Norbert Wronski, Agnieszka Harazin-Lechowska, Anna Muzyk, Krzysztof Makuch, Michal Markiewicz, Janusz Rys, and Agnieszka Wolnicka-Glubisz. "Vemurafenib and Dabrafenib Downregulates RIPK4 Level." Cancers 15, no. 3 (February 1, 2023): 918. http://dx.doi.org/10.3390/cancers15030918.
Повний текст джерелаUebel, Anne, Stefanie Kewitz-Hempel, Edith Willscher, Kathleen Gebhardt, Cord Sunderkötter, and Dennis Gerloff. "Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma." International Journal of Molecular Sciences 24, no. 3 (January 19, 2023): 1963. http://dx.doi.org/10.3390/ijms24031963.
Повний текст джерелаSchreck, Karisa, Andrew Morin, Guisheng Zhao, Bridget Sanford, Adam Green, Kenneth Jones, Anurhada Banerjee, et al. "DDRE-13. DECONVOLUTING MECHANISMS OF RESISTANCE TO BRAF INHIBITORS IN BRAF V600E HUMAN GLIOMA." Neuro-Oncology 22, Supplement_2 (November 2020): ii64. http://dx.doi.org/10.1093/neuonc/noaa215.258.
Повний текст джерелаRomano, David, Lucía García-Gutiérrez, Nourhan Aboud, David J. Duffy, Keith T. Flaherty, Dennie T. Frederick, Walter Kolch, and David Matallanas. "Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma." Life Science Alliance 5, no. 10 (August 29, 2022): e202201445. http://dx.doi.org/10.26508/lsa.202201445.
Повний текст джерелаThompson, Elizabeth L., Jiayi J. Hu, and Laura J. Niedernhofer. "The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma." Cancers 13, no. 9 (May 7, 2021): 2241. http://dx.doi.org/10.3390/cancers13092241.
Повний текст джерелаWattson, Daniel A., Helen Alice Shih, Andrzej Niemierko, Ryan M. Merritt, Donald P. Lawrence, Kevin S. Oh, Ryan J. Sullivan, and Keith Flaherty. "Survival patterns following brain metastases for patients with melanoma in the targeted therapy era." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 9064. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9064.
Повний текст джерелаČepulytė, Rūta, Andrius Žučenka, and Valdas Pečeliūnas. "Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation." Case Reports in Hematology 2020 (October 15, 2020): 1–5. http://dx.doi.org/10.1155/2020/8894031.
Повний текст джерелаPark, Robin, Laércio Lopes da Silva, Sunggon Lee, and Anwaar Saeed. "Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 3557. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3557.
Повний текст джерелаRöck, Ruth, Johanna E. Mayrhofer, Omar Torres-Quesada, Florian Enzler, Andrea Raffeiner, Philipp Raffeiner, Andreas Feichtner, et al. "BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS." Science Advances 5, no. 8 (August 2019): eaav8463. http://dx.doi.org/10.1126/sciadv.aav8463.
Повний текст джерелаKotecha, Rupesh, Jacob A. Miller, Vyshak A. Venur, Alireza M. Mohammadi, Samuel T. Chao, John H. Suh, Gene H. Barnett, et al. "Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome." Journal of Neurosurgery 129, no. 1 (July 2018): 50–59. http://dx.doi.org/10.3171/2017.1.jns162797.
Повний текст джерелаLeclair, Héloïse M., Nina Tardif, Anaïs Paris, Marie-Dominique Galibert, and Sébastien Corre. "Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors." International Journal of Molecular Sciences 21, no. 14 (July 16, 2020): 5025. http://dx.doi.org/10.3390/ijms21145025.
Повний текст джерелаDummer, Reinhard, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Reiney Kudchadkar, Carlos Gomez-Roca, Ryan J. Sullivan, et al. "Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 9028. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9028.
Повний текст джерелаHaselmann, Verena, Christoffer Gebhardt, Ingrid Brechtel, Angelika Duda, Claudia Czerwinski, Antje Sucker, Tim Holland-Letz, Jochen Utikal, Dirk Schadendorf, and Michael Neumaier. "Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy." Clinical Chemistry 64, no. 5 (May 1, 2018): 830–42. http://dx.doi.org/10.1373/clinchem.2017.281543.
Повний текст джерелаHuynh, Sandra, Laurent Mortier, Caroline Dutriaux, Eve Maubec, Marie Boileau, Olivier Dereure, Marie-Therese Leccia, et al. "Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study." Cancers 12, no. 6 (June 23, 2020): 1666. http://dx.doi.org/10.3390/cancers12061666.
Повний текст джерелаSwitzer, Benjamin, Sabah Alaklabi, Arya Mariam Roy, Kristopher Attwood, Chong Wang, Lamya Hamad, Tammy Sessanna, Michele Nanni, Yeliam Patel, and Igor Puzanov. "Toxicity and outcomes of BRAF and MEK inhibitor “ramp-up” dosing strategies for patients with melanoma: A real-world institutional experience." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e21600-e21600. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21600.
Повний текст джерелаSan Lucas, F. Anthony, Scott Kopetz, Paul A. Scheet, and Eduardo Vilar Sanchez. "Discovering new targeted therapies for BRAF mutant-like colorectal cancers." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 3623. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3623.
Повний текст джерелаPóvoa, Antónia Afonso, Elisabete Teixeira, Maria Rosa Bella-Cueto, Rui Batista, Ana Pestana, Miguel Melo, Thalita Alves, et al. "Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma." Cancers 13, no. 9 (April 23, 2021): 2048. http://dx.doi.org/10.3390/cancers13092048.
Повний текст джерелаWeber, Jeffrey S., Keith T. Flaherty, Jeffrey R. Infante, Gerald Steven Falchook, Richard Kefford, Adil Daud, Omid Hamid, et al. "Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 8510. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8510.
Повний текст джерела